TABLE 4.
Patient characteristics of subgroup with thymectomy and thymomas
| Characteristics | Thymomas | Thymectomy | ||||
|---|---|---|---|---|---|---|
| Yes | No | p value | Yes | No | p value | |
| Patients, n | 17 | 73 | 49 | 41 | ||
| Females, n (%) | 8 (47.1) | 47 (64.9) | 0.187 a | 35 (72.0) | 20 (48.8) | 0.028 |
| Age at baseline a , median years (range) | 49.0 (30–73) | 55.0 (18–83) | 0.200b | 40.0 (18–78) | 68.0 (35–83) | <0.001 |
| Immunosuppressive therapy, n (%) | 17 (100) | 63 (86.3) | 0.090 a | 41 (83.6) | 39 (95.1) | 0.085 |
| MGFA‐score at baseline a , n (%) | ||||||
| 0 (remission) | 1 (5.9) | 6 (8.2) | 3 (6.1) | 4 (9.8) | ||
| I | 4 (23.5) | 17 (23.3) | 9 (18.4) | 12 (29.2) | ||
| IIA | 2 (11.8) | 11 (15.1) | 7 (14.3) | 6 (14.6) | ||
| IIB | 3 (17.6) | 16 (21.9) | 15 (30.6) | 4 (9.8) | ||
| IIIA | 2 (11.8) | 8 (11.0) | 4 (8.2) | 6 (14.6) | ||
| IIIB | 4 (23.5) | 7 (9.6) | 7 (14.3) | 4 (9.8) | ||
| IVA | 0 (0.0) | 4 (5.5) | 2 (4.1) | 2 (4.9) | ||
| IVB | 1 (5.9) | 2 (2.7) | 1 (2.0) | 2 (4.9) | ||
| V | 0 (0.0) | 2 (2.7) | 1 (2.0) | 1 (2.4) | ||
| Severity of MG at baseline a , n (%) | 0.312 a | 0.354 | ||||
| MGFA 0—IIB | 10 (58.8) | 50 (68.5) | 34 (69.4) | 26 (63.4) | ||
| MGFA IIIA—IV | 7 (41.2) | 23 (31.5) | 15 (30.6) | 15 (36.6) | ||
| Remission of MG after baseline, n (%) | 15 (88.2) | 61 (83.6) | 0.632 a | 42 (85.7) | 34 (82.9) | 0.716 |
| Remission of MG after baseline, median months (range) | 13 (3–163) | 15 (2–66) | 0.459b | 19 (3–163) | 11 (2–35) | 0.027 |
Abbreviation: MG, myasthenia gravis; MGFA, Myasthenia Gravis Foundation of America.
a
At baseline: first analysis of anti‐acetylcholine receptor antibody serum levels in the Maastricht University Medical Center.